I-Mab
NASDAQ:IMAB

  • LAST PRICE
    0.9322
  • TODAY'S CHANGE (%)
    -0.0187 (-1.9666%)
  • Bid / Lots
    0.9300/ 36
  • Ask / Lots
    0.9890/ 20
  • Open / Previous Close
    0.9700 / 0.9509
  • Day Range
    0.9301
    0.9700
  • 52 Week Range
    0.8989
    2.5362
  • Volume
    103,944

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 21, 2024

  • Nov 15, 2024

  • Nov 14, 2024

      Show headlines and story abstract

    • 7:00AM ET on Thursday Nov 14, 2024 by PR Newswire
      Companies Mentioned: IMAB

      -- Givastomig data presented at ESMO 2024 and SITC 2024 highlights encouraging monotherapy data

      -- On track to dose first patient in randomized Phase 2 study ofuliledlimab in first-line mNSCLC in 1H 2025

    • 7:00AM ET on Thursday Nov 14, 2024 by Dow Jones
      Companies Mentioned: IMAB
      Total revenues -- 315 -- 627 Expenses Research and development expenses (Note 1) (4,475) (5,088) (15,740) (13,286) Administrative expenses (Note 2) (7,937) (5,861) (22,315) (19,895) ----------- ------------- ----------- ----------- Loss from operations (12,412) (10,634) (38,055) (32,554) Interest income 2,449 2,483 5,289 6,989 Other income (expenses), net (10,528) 2,379 (5,048) (9,102) Equity in loss of affiliates (Note 3) -- (2,449) (1,038) (10,640) Loss from continuing operations before income tax expense (20,491) (8,221) (38,852) (45,307) Income tax expense -- -- -- -- ----------- ------------- ----------- ----------- Loss from continuing operations $ (20,491) $ (8,221) $ (38,852) $ (45,307) Discontinued operations: Loss from operations of discontinued operations (Note 4) $ -- $ (25,035) $ (6,898) $ (94,522) Income tax expense -- -- -- -- Gain on sale of discontinued operations -- -- 32,582 -- ----------- ------------- ----------- ----------- Income (loss) from discontinued operations $ -- $ (25,035) $ 25,684 $ (94,522) Net loss attributable to I-Mab $ (20,491) $ (33,256) $ (13,168) $ (139,829) =========== ============= =========== =========== Net loss attributable to ordinary shareholders $ (20,491) $ (33,256) $ (13,168) $ (139,829) Net loss attributable to I-Mab $ (20,491) $ (33,256) $ (13,168) $ (139,829) Foreign currency translation adjustments net of tax 1,071 (13,547) (494) 8,887 ----------- ------------- ----------- ----------- Total comprehensive loss attributable to I-Mab $ (19,420) $ (46,803) $ (13,662) $ (130,942) Net loss from continuing operations per share attributable to ordinary shareholders --Basic and diluted $ (0.11) $ (0.04) $ (0.21) $ (0.24) Net loss from continuing operations per ADS attributable to ordinary shareholders (Note 5) --Basic and diluted $ (0.25) $ (0.09) $ (0.48) $ (0.55) Net income (loss) from discontinued operations per share attributable to ordinary shareholders --Basic and diluted $ - $ (0.13) $ 0.14 $ (0.49) Net income (loss) from discontinued operations per ADS attributable to ordinary shareholders (Note 5) --Basic and diluted $ - $ (0.30) $ 0.32 $ (1.13) Net loss attributable to ordinary shareholders --Basic and diluted $ (0.11) $ (0.17) $ (0.07) $ (0.73) Net loss per ADS attributable to ordinary shareholders (Note 5) --Basic and diluted $ (0.25) $ (0.39) $ (0.16) $ (1.68) Weighted-average number of ordinary shares outstanding --Basic and diluted 187,440,440 192,922,665 186,485,241 191,306,670

Peers Headlines